Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

From Startup Anika Therapeutics

Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-resumes-global-distribution-hyalofast-hyalograft-c-and

Company Expands HYALOFAST Commercial Reach in Asia, the Middle East
and Latin America
BEDFORD, Mass.–(BUSINESS WIRE)–Dec. 4, 2018–
Anika
Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic
and regenerative medicines company specializing in therapeutics based on
its proprietary hyaluronic
acid (“HA”) technology, today announced that it has
resumed global distribution of its solid HA-based treatments, including HYALOFAST,
a biodegradable, HA-based cartilage repair scaffold, after a voluntary,
non-safety related recall in the second quarter of 2018. Following
recent regulatory approvals in Thailand, the United Arab Emirates and
Colombia, HYALOFAST has a commercial footprint in approximately 15
countries.

“Since May, our quality and operations teams have worked tirelessly
to get us back on line to resume shipments before the end of this year,
and we’ve delivered on that promise,” said Joseph Darling, President
and CEO, Anika Therapeutics. “We are excited to bring the benefits of
these products back to the patients who need them. HYALOFAST, in
particular, is a truly remarkable advancement in the treatment of
cartilage defects due to its flexible minimally-invasive means of
application and adaptive fit to individual patient needs. These features
have led to an overwhelmingly positive physician response to the therapy
and illustrate its significant advantages over traditional microfracture
surgeries and conventional scaffolds.”
HYALOFAST
is a non-woven, single-step, off-the-shelf, biodegradable HA-based
scaffold for hyaline-like cartilage regeneration to treat cartilage
injuries and defects. To date, the Company has seen HYALOFAST used to
treat more than 15,000 patients internationally and has compiled strong
eight-year patient follow-up data. HYALOFAST is pending regulatory
submission in the United States and its FastTRACK Phase III trial is
currently enrolling patients across the U.S. and Europe.

About Anika Therapeutics, Inc.
Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic medicines company based in Bedford, Massachusetts. Anika is
committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically meaningful
therapies along the continuum of care, from palliative pain management
to regenerative tissue repair. The Company has over two decades of
global expertise developing, manufacturing, and commercializing more
than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181204006033/en/
Source: Anika Therapeutics, Inc.

For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial OfficerFor Media
Inquiries:W2O GroupSonal Vasudev, 917-523-1418sonal@w2ogroup.com

Please visit their site for more information: Anika Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-12-05 19:50:37